Outcomes of first-line pembrolizumab monotherapy for PD-L1–positive (TPS ≥50%) metastatic NSCLC at US oncology practices

In this Publication Perspective, lead author Vamsidhar Velcheti, New York University, provides a summary of the article ‘Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices’ published in Immunotherapy that looks at real-world outcomes with first-line pembrolizumab monotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor expression ≥50%.

About the author:

Vamsidhar Velcheti, MD FACP FCCP is a medical oncologist with expertise in thoracic oncology and cancer immunotherapy. He is currently the Director of Thoracic Medical oncology at the New York University, New York, NY, USA. His current work focuses on novel immunotherapy strategies to treat lung cancer and biomarker discovery.

Original publication:

Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices
Vamsidhar Velcheti, Sheenu Chandwani, Xin Chen, M Catherine Pietanza, Bilal Piperdi & Thomas Burke
Immunotherapy (2019) doi/10.2217/imt-2019-0177